biostudies-literatureUnknown13(3)Fauvre A<h4>Background</h4>Colorectal cancer (CRC) is the third most common cancer type and one of the leading causes of cancer-related death worldwide. The treatment of advanced metastatic CRC relies on classical chemotherapy combinations (5-fluorouracil, oxaliplatin or irinotecan). However, their use is limited by the emergence of resistance mechanisms, including to oxaliplatin. In this context, we recently showed that the combination of oxaliplatin and ataxia telangiectasia and Rad3-related protein inhibition (VE-822) is synergistic and may have a potential therapeutic effect in metastatic CRC management.<h4>Methods</h4>In this study, we investigated the role of the VE-822+oxaliplatin (Vox) combination on the immune response and its potential synergy with an anti-programmed-cell Death receptor-Journal for immunotherapy of cancere010791https://www.ebi.ac.uk/biostudies/studies/S-EPMC11950992biostudies-literatureOxaliplatin, ATR inhibitor and anti-PD-1 antibody combination therapy controls colon carcinoma growth, induces local and systemic changes in the immune compartment, and protects against tumor rechallenge in mice.PMC11950992Andrade AFVezzio-Vie NCombes EMichaud HACulerier ESgarbura OMilazzo LAHouede NGarambois VQuenet FJeanson LAtis SCorbeau IFaget JMarchive CBonnefoy NUrsino CLossaint GFauvre ATosi DKhellaf LGongora CfalseOxaliplatin, ATR inhibitor and anti-PD-1 antibody combination therapy controls colon carcinoma growth, induces local and systemic changes in the immune compartment, and protects against tumor rechallenge in mice.<h4>Background</h4>Colorectal cancer (CRC) is the third most common cancer type and one of the leading causes of cancer-related death worldwide. The treatment of advanced metastatic CRC relies on classical chemotherapy combinations (5-fluorouracil, oxaliplatin or irinotecan). However, their use is limited by the emergence of resistance mechanisms, including to oxaliplatin. In this context, we recently showed that the combination of oxaliplatin and ataxia telangiectasia and Rad3-related protein inhibition (VE-822) is synergistic and may have a potential therapeutic effect in metastatic CRC management.<h4>Methods</h4>In this study, we investigated the role of the VE-822+oxaliplatin (Vox) combination on the immune response and its potential synergy with an anti-programmed-cell Death receptor-2025-01-01T00:00:00Z2025 Mar2026-06-02T06:33:10.134Z2025-07-11T03:03:51.99ZS-EPMC119509924013983310.1136/jitc-2024-010791